UB Paderborn / Katalog / Suche / in CDI

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

The New England journal of medicine, 2016-08, Vol.375 (5), p.422-434

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacity of dupilumab in severe idiopathic cold urticaria: a case report

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2182620-2182620

2023

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Journal of the American Academy of Dermatology, 2019-07, Vol.81 (1), p.143-151

2019

Link zum Volltext

Verfügbarkeit prüfen

A systematic review of dimensions evaluating patient experience in chronic illness

Health and quality of life outcomes, 2019-01, Vol.17 (1), p.19-19, Article 19

2019

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab for skin reactions associated with anti‐tumor necrosis factor‐α agents in patients with inflammatory bowel diseases: A single‐center retrospective study

Journal of dermatology, 2019-04, Vol.46 (4), p.322-327

2019

Link zum Volltext

Verfügbarkeit prüfen

Patient Burden is Associated with Alterations in Quality of Life in Adult Patients with Atopic Dermatitis: Results from the ECLA Study

Acta dermato-venereologica, 2018, Vol.98 (7), p.713-714

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

BMJ open, 2023-02, Vol.13 (2), p.e060536-e060536

2023

Link zum Volltext

Verfügbarkeit prüfen

Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up

Journal of the American Academy of Dermatology, 2012-10, Vol.67 (4), p.623-629

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

Acta dermato-venereologica, 2023-10, Vol.103, p.adv14153-adv14153

2023

Link zum Volltext

Verfügbarkeit prüfen

Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy

Journal of the American Academy of Dermatology, 2012-03, Vol.66 (3), p.424-429

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns

Acta dermato-venereologica, 2020-08, Vol.100 (15), p.adv00248-adv00248

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of oral alitretinoin for the treatment of Darier disease: A case report

Journal of the American Academy of Dermatology, 2014-08, Vol.71 (2), p.e46-e48

2014

Link zum Volltext

Verfügbarkeit prüfen

Combining Omalizumab with Another Biotherapy

Acta dermato-venereologica, 2019-04, Vol.99 (4), p.448-449

2019

Link zum Volltext

Verfügbarkeit prüfen

The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease

American journal of clinical dermatology, 2007-01, Vol.8 (2), p.67-77

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa

EJD. European journal of dermatology, 2012-09, Vol.22 (5), p.640-644

2012

Link zum Volltext

Verfügbarkeit prüfen

Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients

Dermatology (Basel), 2014-01, Vol.229 (2), p.116

2014

Link zum Volltext

Verfügbarkeit prüfen

How to Define Mild to Severe Hidradenitis Suppurativa? A Simple New Tool Based on Latent Class Analysis of EPIVER Data Study

Clinical, cosmetic and investigational dermatology, 2022-06, Vol.15, p.1091-1103

2022

Link zum Volltext

Verfügbarkeit prüfen

Individual Burden of Psoriasis (I-BOP): Building and Validation of a New Scoring Tool for Patients with Psoriasis

Clinical, cosmetic and investigational dermatology, 2020-01, Vol.13, p.325-332

2020

Link zum Volltext

Verfügbarkeit prüfen

Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders

Dermatology (Basel), 2008-01, Vol.216 (4), p.330

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata

Dermatology (Basel), 2016-01, Vol.232 (2), p.242

2016

Link zum Volltext

Verfügbarkeit prüfen

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

The Lancet (British edition), 2015-08, Vol.386 (9993), p.552-561

2015

Link zum Volltext

Verfügbarkeit prüfen

42640 Efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Final results from the Phase 3 SUNSHINE and SUNRISE trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB156-AB156

2023

Link zum Volltext

Verfügbarkeit prüfen

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Journal of the European Academy of Dermatology and Venereology, 2020-11, Vol.34 (11), p.e676-e679

2020

Link zum Volltext

Verfügbarkeit prüfen

Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases

Journal of the American Academy of Dermatology, 2020-07, Vol.83 (1), p.199-201

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Efficacity of dupilumab in severe idiopathic cold urticaria: a case report

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

A systematic review of dimensions evaluating patient experience in chronic illness

Ustekinumab for skin reactions associated with anti‐tumor necrosis factor‐α agents in patients with inflammatory bowel diseases: A single‐center retrospective study

Patient Burden is Associated with Alterations in Quality of Life in Adult Patients with Atopic Dermatitis: Results from the ECLA Study

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)

Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy

Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns

Efficacy of oral alitretinoin for the treatment of Darier disease: A case report

Combining Omalizumab with Another Biotherapy

The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease

Efficacy and tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa

Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients

How to Define Mild to Severe Hidradenitis Suppurativa? A Simple New Tool Based on Latent Class Analysis of EPIVER Data Study

Individual Burden of Psoriasis (I-BOP): Building and Validation of a New Scoring Tool for Patients with Psoriasis

Melanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders

Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

42640 Efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: Final results from the Phase 3 SUNSHINE and SUNRISE trials

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19

Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases

Suchergebnisse filtern